Heart Defects, Congenital
Conditions
Brief summary
This trial will evaluate the efficacy and safety of the modified Blalock-Taussig shunt (MBTS) compared to the right ventricle to pulmonary artery (RV-to-PA) shunt; compare the effect of the MBTS to that of the RV-to-PA shunt on the incidence of death or cardiac transplantation at 12 months post randomization; and compare the effect of the two shunts on intensive care unit (ICU) morbidity, unintended cardiovascular interventional procedures, right ventricular function, tricuspid valve regurgitation, pulmonary artery growth, and neurodevelopmental outcome.
Detailed description
BACKGROUND: Hypoplastic left heart syndrome (HLHS) and related single right ventricle anomalies are the highest risk congenital cardiovascular malformations. Surgical repair begins with the Norwood procedure during the newborn period, a stage II procedure at 4 to 6 months of age, and Fontan procedure at 18 to 36 months. The Norwood procedure remains one of the highest risk procedures in congenital heart surgery. A few small nonrandomized studies of a novel approach to the Norwood procedure have reported improved outcomes. This new approach uses a RV-to-PA shunt to provide pulmonary blood flow rather than the standard MBTS. This multi-center, randomized clinical trial will evaluate early and intermediate-term outcomes for patients undergoing a Norwood procedure with either the RV-to-PA shunt or the MBTS. This study has been approved by the Institutional Review/Research Ethics Boards of all participating clinical centers: Hospital for Sick Children, Toronto, Canada Children's Hospital Boston, Boston, MA Columbia College of Physicians and Surgeons, New York, NY Children's Hospital of Philadelphia, Philadelphia, PA Duke University Medical Center, Durham, NC Brody School of Medicine at East Carolina University, Greenville, NC Wake Forest Baptist Medical Center, Winston Salem, NC Medical University of South Carolina, Charleston, SC Children's Hospital of Wisconsin, Milwaukee, WI University of Michigan, Ann Arbor, MI Cincinnati Children's Hospital Medical Center, Cincinnati, OH Children's Hospital of Los Angeles, Los Angeles, CA Egleston Children's Hospital, Emory University, Atlanta, GA Congenital Heart Institute of Florida, University of South Florida, St. Petersburg, FL Alfred I. duPont Hospital for Children, Wilmington, DE DESIGN NARRATIVE: This is a prospective, randomized clinical trial of the RV-to-PA shunt versus MBTS in patients undergoing a Norwood procedure.
Interventions
Performed at stage I palliative surgery for babies born with HLHS
Performed at stage I palliative surgery for babies born with HLHS
Sponsors
Study design
Eligibility
Inclusion criteria
* Diagnosis of hypoplastic left heart syndrome or related single, morphologic right ventricle anomaly * Planned Norwood procedure * Informed consent of parent(s) or legal guardian
Exclusion criteria
* Single, morphologic left ventricle anomaly * Preoperative identification of anatomy rendering either an MBTS or an RV-to-PA shunt technically impossible * Any major congenital abnormality (i.e., congenital diaphragmatic hernia, tracheoesophageal fistula) or acquired extra-cardiac disorder (e.g., meconium aspiration with need for high frequency ventilation, persistent renal failure requiring dialysis) that, in the opinion of the investigator, could independently affect the likelihood of the subject meeting the primary endpoint
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients Who Died or Received a Heart Transplant | Measured at 12 months | The primary outcome was the proportion of patients who died or had cardiac transplantation 12 months after randomization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Echocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA) | Measured post-Norwood, an average of 17 days post-Norwood | Right ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age. |
| Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA | Measured pre-stage II surgery, an average of 15 days pre-stage II surgery | Right ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age. |
| Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA | Measured post-Norwood, an average of 17 days post-Norwood | Right ventricular end-systolic volume indexed to BSA. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age. |
| Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction | Measured post-Norwood, an average of 17 days post-Norwood | Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age. |
| Angiographic Findings: Left Pulmonary Artery Size | Measured pre-stage II surgery, on average 26 days prior to stage II palliation | Diameter of distal left pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II). |
| Proportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial | From Randomization to the End of the Trial, an average of 32 months | This secondary outcome was the proportion of deaths or cardiac transplantation over time from randomization to the end of the trial. |
| Unintended Cardiovascular Interventional Procedures | From Randomization to 12 months | Unintended cardiovascular procedures included balloon dilation of the shunt or branch pulmonary arteries, stent placement in the shunt or branch pulmonary arteries, shunt revision, crossover between MBTS and RVPAS shunt, balloon dilation, stent placement or surgical revisions of the neo-aorta, and pulmonary artery reconstructions, other than those undertaken as a standard component of the stage II procedure. The number of cardiovascular procedures was analyzed; trial participants may have had more than one unintended cardiovascular. procedure. |
| Complications: Total Number Experienced During Norwood Hospitalization | Norwood Hospitalization, an average of 36 days | Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious. |
| Complications: Total Number Experienced From Norwood Discharge to Stage II Discharge | From Norwood Discharge to Stage II discharge, an average of 4.2 months | Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious. |
| Complications: Total Number Experienced From Stage II Discharge to 14 Months of Age | From Stage II Discharge to 14 Months of Age, an average of 8.9 months | Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious. |
| Angiographic Findings: Right Pulmonary Artery Size | Measured pre-stage II surgery, on average 26 days prior to stage II palliation | Diameter of distal right pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II). |
Countries
Canada, United States
Participant flow
Recruitment details
Subjects undergoing a Norwood were randomized to MBTS or RVPAS at 15 North American centers.
Pre-assignment details
There were no pre-assignment requirements beyond the initial screening criteria.
Participants by arm
| Arm | Count |
|---|---|
| MBTS Blalock-Taussig pulmonary artery shunt | 275 |
| RVPAS Right ventricular to pulmonary artery shunt | 274 |
| Total | 549 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Did not receive intervention | 3 | 2 |
| Overall Study | Lost to Follow-up | 1 | 0 |
Baseline characteristics
| Characteristic | MBTS | RVPAS | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 275 Participants | 274 Participants | 549 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 5.1 days STANDARD_DEVIATION 4.1 | 5.0 days STANDARD_DEVIATION 4 | 5.1 days STANDARD_DEVIATION 4 |
| Region of Enrollment Canada | 7 participants | 8 participants | 15 participants |
| Region of Enrollment United States | 268 participants | 266 participants | 534 participants |
| Sex: Female, Male Female | 107 Participants | 102 Participants | 209 Participants |
| Sex: Female, Male Male | 168 Participants | 172 Participants | 340 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 249 / 275 | 251 / 274 |
| serious Total, serious adverse events | 146 / 275 | 112 / 274 |
Outcome results
Proportion of Patients Who Died or Received a Heart Transplant
The primary outcome was the proportion of patients who died or had cardiac transplantation 12 months after randomization.
Time frame: Measured at 12 months
Population: 555 subjects were enrolled in the study; 5 of these subjects were excluded from analyses because a Norwood procedure was not performed; 1 subject was excluded because the subject withdrew before the 12-month follow-up, 12-month status was unknown. The data were analyzed on an intention to treat basis, subjects were analyzed as randomized.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| MBTS | Proportion of Patients Who Died or Received a Heart Transplant | 100 Participants |
| RVPAS | Proportion of Patients Who Died or Received a Heart Transplant | 72 Participants |
Angiographic Findings: Left Pulmonary Artery Size
Diameter of distal left pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).
Time frame: Measured pre-stage II surgery, on average 26 days prior to stage II palliation
Population: These patients had pre-stage II palliation visits with acceptable cardiac catheterizations.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MBTS | Angiographic Findings: Left Pulmonary Artery Size | 5.2 mm | Standard Deviation 1.5 |
| RVPAS | Angiographic Findings: Left Pulmonary Artery Size | 5.4 mm | Standard Deviation 1.7 |
Angiographic Findings: Right Pulmonary Artery Size
Diameter of distal right pulmonary artery. Angiograms were performed at the time points relative to the second palliative surgery (pre-Stage II).
Time frame: Measured pre-stage II surgery, on average 26 days prior to stage II palliation
Population: These patients had pre-stage II palliation visits with acceptable cardiac catheterizations.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MBTS | Angiographic Findings: Right Pulmonary Artery Size | 6.1 mm | Standard Deviation 2 |
| RVPAS | Angiographic Findings: Right Pulmonary Artery Size | 5.4 mm | Standard Deviation 1.7 |
Complications: Total Number Experienced During Norwood Hospitalization
Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.
Time frame: Norwood Hospitalization, an average of 36 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| MBTS | Complications: Total Number Experienced During Norwood Hospitalization | 850 complications |
| RVPAS | Complications: Total Number Experienced During Norwood Hospitalization | 792 complications |
Complications: Total Number Experienced From Norwood Discharge to Stage II Discharge
Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.
Time frame: From Norwood Discharge to Stage II discharge, an average of 4.2 months
Population: These numbers reflect those patients who were discharged from the hospital after the Norwood procedure and were transplant free.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| MBTS | Complications: Total Number Experienced From Norwood Discharge to Stage II Discharge | 367 complications |
| RVPAS | Complications: Total Number Experienced From Norwood Discharge to Stage II Discharge | 515 complications |
Complications: Total Number Experienced From Stage II Discharge to 14 Months of Age
Complications, reported as 'Other Adverse Events' in the safety section, are those adverse events that were not considered serious. Many normal peri-operative occurrences meet the standard criteria of an adverse event; therefore, for this trial a serious adverse event was (a) death, (b) acute shunt failure requiring intervention, (c) cardiac arrest requiring CPR and medications, (d) cardiopulmonary insufficiency requiring ECMO, (e) cardiovascular re-operation (unplanned), (f) necrotizing enterocolitis requiring laparotomy, and (g) any event considered by the study investigator as serious.
Time frame: From Stage II Discharge to 14 Months of Age, an average of 8.9 months
Population: These numbers reflect the number of patients who were discharged from the hospital after the Stage 2 procedure and were transplant-free.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| MBTS | Complications: Total Number Experienced From Stage II Discharge to 14 Months of Age | 81 complications |
| RVPAS | Complications: Total Number Experienced From Stage II Discharge to 14 Months of Age | 145 complications |
Echocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA)
Right ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Time frame: Measured post-Norwood, an average of 17 days post-Norwood
Population: 241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or measures were not able to be obtained to calculate the volumes.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MBTS | Echocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA) | 91.2 ml/m^2.6 |
| RVPAS | Echocardiographic Measures of Heart Size and Function: Right Ventricle (RV) End-diastolic Volume Indexed to Body Surface Area (BSA) | 86.5 ml/m^2.6 |
Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction
Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Time frame: Measured pre-stage II surgery, an average of 15 days pre-stage II surgery
Population: 181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MBTS | Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction | 42.9 Percentage of RV end-diastolic volume | Standard Deviation 7.9 |
| RVPAS | Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction | 44.7 Percentage of RV end-diastolic volume | Standard Deviation 8.3 |
Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction
Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Time frame: Measured at 14 months of age
Population: 184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MBTS | Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction | 42.7 Percentage of RV end-diastolic volume | Standard Deviation 7.4 |
| RVPAS | Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction | 42.7 Percentage of RV end-diastolic volume | Standard Deviation 8 |
Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction
Right ventricular ejection fraction: 100 x (RV end-diastolic volume - RV end-systolic volume)/RV end-diastolic volume. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Time frame: Measured post-Norwood, an average of 17 days post-Norwood
Population: 241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes used to calculate the ejection fraction.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MBTS | Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction | 44.5 Percentage of RV end-diastolic volume | Standard Deviation 7.6 |
| RVPAS | Echocardiographic Measures of Heart Size and Function: RV Ejection Fraction | 48.5 Percentage of RV end-diastolic volume | Standard Deviation 7.6 |
Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA
Right ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Time frame: Measured at 14 months of age
Population: 184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MBTS | Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA | 83.3 ml/m^2.6 |
| RVPAS | Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA | 88.9 ml/m^2.6 |
Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA
Right ventricular end-diastolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Time frame: Measured pre-stage II surgery, an average of 15 days pre-stage II surgery
Population: 181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MBTS | Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA | 113.4 ml/m^2.6 |
| RVPAS | Echocardiographic Measures of Heart Size and Function: RV End-diastolic Volume Indexed to BSA | 105.2 ml/m^2.6 |
Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA
Right ventricular end-systolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Time frame: Measured pre-stage II surgery, an average of 15 days pre-stage II surgery
Population: 181 and 214 patients remained in the MBTS and RVPAS groups at the time of the pre-Stage II echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MBTS | Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA | 63.2 ml/m^2.6 |
| RVPAS | Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA | 57.9 ml/m^2.6 |
Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA
Right ventricular end-systolic volume indexed to BSA\^1.3. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Time frame: Measured at 14 months of age
Population: 184 and 179 patients remained in the MBTS and RVPAS groups at the 14-months of age echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MBTS | Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA | 45.4 ml/m^2.6 |
| RVPAS | Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA | 50.5 ml/m^2.6 |
Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA
Right ventricular end-systolic volume indexed to BSA. Echocardiograms were performed at time points relative to the two palliative surgeries (post-Norwood and pre-Stage II) as well as at the specific time point of 14 months of age.
Time frame: Measured post-Norwood, an average of 17 days post-Norwood
Population: 241 and 239 patients remained in the MBTS and RVPAS groups at the time of the post-Norwood echo. Of these, some patients did not have acceptable echos or not all measures were able to be obtained to calculate the volumes.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MBTS | Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA | 50.1 ml/m^2.6 |
| RVPAS | Echocardiographic Measures of Heart Size and Function: RV End-systolic Volume Indexed to BSA | 44.2 ml/m^2.6 |
Proportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial
This secondary outcome was the proportion of deaths or cardiac transplantation over time from randomization to the end of the trial.
Time frame: From Randomization to the End of the Trial, an average of 32 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| MBTS | Proportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial | 107 Participants |
| RVPAS | Proportion of Deaths or Heart Transplants Over Time From Randomization to the End of the Trial | 88 Participants |
Unintended Cardiovascular Interventional Procedures
Unintended cardiovascular procedures included balloon dilation of the shunt or branch pulmonary arteries, stent placement in the shunt or branch pulmonary arteries, shunt revision, crossover between MBTS and RVPAS shunt, balloon dilation, stent placement or surgical revisions of the neo-aorta, and pulmonary artery reconstructions, other than those undertaken as a standard component of the stage II procedure. The number of cardiovascular procedures was analyzed; trial participants may have had more than one unintended cardiovascular. procedure.
Time frame: From Randomization to 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| MBTS | Unintended Cardiovascular Interventional Procedures | 192 procedures |
| RVPAS | Unintended Cardiovascular Interventional Procedures | 252 procedures |